{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:19:42Z","timestamp":1793056782496,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72204-2","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T16:26:59Z","timestamp":1777134419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Joan","family":"Choo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-4697","authenticated-orcid":false,"given":"Mai Chan","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willa Wen-You","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4916-0657","authenticated-orcid":false,"given":"Crystal Tze Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Xian","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong Boon","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khi Yung","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9773-411X","authenticated-orcid":false,"given":"Ryan Yong Kiat","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ying Joey","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-9840","authenticated-orcid":false,"given":"Lit-Hsin","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-6339","authenticated-orcid":false,"given":"Paolo","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Prisciandaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Randon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Damonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Micarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5393-6713","authenticated-orcid":false,"given":"Elisa","family":"Scarselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-4841","authenticated-orcid":false,"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Marmorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8903-8843","authenticated-orcid":false,"given":"Jeffrey Chun Tatt","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen Wei","family":"Neo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4623-4633","authenticated-orcid":false,"given":"Li Yen","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig Ryan","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhila","family":"Balachander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana GS","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You Yi","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Renia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhra Kumar","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-5262","authenticated-orcid":false,"given":"David","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-7153","authenticated-orcid":false,"given":"Joe P. S.","family":"Yeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-1368","authenticated-orcid":false,"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":false,"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"72204_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"72204_CR2","doi-asserted-by":"crossref","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin. 71, 209-249 (2021).","DOI":"10.3322\/caac.21660"},{"key":"72204_CR3","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"72204_CR4","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","volume":"6","author":"EX Chen","year":"2020","unstructured":"Chen, E. X. et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 Study. JAMA Oncol. 6, 831\u2013838 (2020).","journal-title":"JAMA Oncol."},{"key":"72204_CR5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","volume":"20","author":"C Eng","year":"2019","unstructured":"Eng, C. et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 20, 849\u2013861 (2019).","journal-title":"Lancet Oncol."},{"key":"72204_CR6","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1158\/1078-0432.CCR-20-0817","volume":"26","author":"G Randon","year":"2020","unstructured":"Randon, G., Pagani, F. & Pietrantonio, F. MGMT promoter methylation as a target in metastatic colorectal cancer: rapid turnover and use of folates alter its study-response. Clin. Cancer Res. 26, 3495 (2020).","journal-title":"Clin. Cancer Res."},{"key":"72204_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/annonc\/mdt547","volume":"25","author":"F Pietrantonio","year":"2014","unstructured":"Pietrantonio, F. et al. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann. Oncol. 25, 404\u2013408 (2014).","journal-title":"Ann. Oncol."},{"key":"72204_CR8","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/2159-8290.CD-21-1434","volume":"12","author":"G Crisafulli","year":"2022","unstructured":"Crisafulli, G. et al. Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. Cancer Discov. 12, 1656\u20131675 (2022).","journal-title":"Cancer Discov."},{"key":"72204_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature24673","volume":"552","author":"G Germano","year":"2017","unstructured":"Germano, G. et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552, 116\u2013120 (2017).","journal-title":"Nature"},{"key":"72204_CR10","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.cell.2017.09.048","volume":"171","author":"BB Campbell","year":"2017","unstructured":"Campbell, B. B. et al. Comprehensive analysis of hypermutation in human cancer. Cell 171, 1042\u201356.e10 (2017).","journal-title":"Cell"},{"key":"72204_CR11","doi-asserted-by":"crossref","unstructured":"Klempner, S. J., et al. Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: a Proof-of-Concept Case. JCO Precis. Oncol. 4, 614\u2013619 (2020).","DOI":"10.1200\/PO.20.00034"},{"key":"72204_CR12","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/JCO.21.02583","volume":"40","author":"F Morano","year":"2022","unstructured":"Morano, F. et al. Temozolomide followed by combination with low-dose Ipilimumab and Nivolumab in patients with microsatellite-stable, O6-Methylguanine\u2013DNA methyltransferase\u2013silenced metastatic colorectal cancer: the MAYA Trial. J. Clin. Oncol. 40, 1562\u20131573 (2022).","journal-title":"J. Clin. Oncol."},{"key":"72204_CR13","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","volume":"187","author":"C Swanton","year":"2024","unstructured":"Swanton, C. et al. Embracing cancer complexity: hallmarks of systemic disease. Cell 187, 1589\u20131616 (2024).","journal-title":"Cell"},{"key":"72204_CR14","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1111\/febs.15028","volume":"286","author":"J Zhang","year":"2019","unstructured":"Zhang, J., Shi, Z., Xu, X., Yu, Z. & Mi, J. The influence of microenvironment on tumor immunotherapy. FEBS J. 286, 4160\u20134175 (2019).","journal-title":"FEBS J."},{"key":"72204_CR15","doi-asserted-by":"crossref","unstructured":"Schwen, L. O. et al. Data-driven discovery of immune contexture biomarkers. Front. Oncol. 8, 627 (2018).","DOI":"10.3389\/fonc.2018.00627"},{"key":"72204_CR16","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1053\/j.gastro.2021.06.064","volume":"161","author":"M Bortolomeazzi","year":"2021","unstructured":"Bortolomeazzi, M. et al. Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts. Gastroenterology 161, 1179\u20131193 (2021).","journal-title":"Gastroenterology"},{"key":"72204_CR17","doi-asserted-by":"crossref","unstructured":"Santiago-S\u00e1nchez, G. S. et al. Biological functions and therapeutic potential of Lipocalin 2 in cancer. Int. J. Mol. Sci. 21, 4365 (2020).","DOI":"10.3390\/ijms21124365"},{"key":"72204_CR18","doi-asserted-by":"crossref","unstructured":"Hidalgo, I., Sorolla, M. A., Sorolla, A., Salud, A. & Parisi, E. Secreted Phospholipases A2: drivers of inflammation and cancer. Int. J. Mol. Sci. 25, 12408 (2024).","DOI":"10.3390\/ijms252212408"},{"key":"72204_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth, N., Wicha, M. S. & Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17, 559\u2013572 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"72204_CR20","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.cell.2020.07.005","volume":"182","author":"CM Sch\u00fcrch","year":"2020","unstructured":"Sch\u00fcrch, C. M. et al. Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. Cell 182, 1341\u201359.e19 (2020).","journal-title":"Cell"},{"key":"72204_CR21","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960\u20131964 (2006).","journal-title":"Science"},{"key":"72204_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02421-1","volume":"20","author":"K Jia","year":"2022","unstructured":"Jia, K. et al. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Med. 20, 223 (2022).","journal-title":"BMC Med."},{"key":"72204_CR23","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558 (2018).","journal-title":"Nat. Med."},{"key":"72204_CR24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775\u2013790 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72204_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303\u2013312 (2013).","journal-title":"Lancet"},{"key":"72204_CR26","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909\u20131919 (2015).","journal-title":"N. Engl. J. Med."},{"key":"72204_CR27","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager, G. W. et al. Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388, 1657\u20131667 (2023).","journal-title":"N. Engl. J. Med."},{"key":"72204_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402, 41\u201353 (2023).","journal-title":"Lancet"},{"key":"72204_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45960-2","volume":"15","author":"A Saeed","year":"2024","unstructured":"Saeed, A. et al. Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nat. Commun. 15, 1533 (2024).","journal-title":"Nat. Commun."},{"key":"72204_CR30","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/1078-0432.CCR-20-3416","volume":"27","author":"S Cousin","year":"2021","unstructured":"Cousin, S. et al. Regorafenib-Avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II Trial. Clin. Cancer Res. 27, 2139\u20132147 (2021).","journal-title":"Clin. Cancer Res."},{"key":"72204_CR31","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka, S. et al. Regorafenib Plus Nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib Trial (REGONIVO, EPOC1603). J. Clin. Oncol. 38, 2053\u20132061 (2020).","journal-title":"J. Clin. Oncol."},{"key":"72204_CR32","doi-asserted-by":"publisher","first-page":"94-","DOI":"10.1200\/JCO.2021.39.3_suppl.94","volume":"39","author":"C Gomez-Roca","year":"2021","unstructured":"Gomez-Roca, C. et al. LEAP-005: a phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors\u2014Results from the colorectal cancer cohort. J. Clin. Oncol. 39, 94- (2021).","journal-title":"J. Clin. Oncol."},{"key":"72204_CR33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2022.03.026","volume":"169","author":"RD Kim","year":"2022","unstructured":"Kim, R. D. et al. A phase I\/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur. J. Cancer 169, 93\u2013102 (2022).","journal-title":"Eur. J. Cancer"},{"key":"72204_CR34","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/2767-9764.CRC-23-0045","volume":"3","author":"M Cecchini","year":"2023","unstructured":"Cecchini, M. et al. Quantitative DNA repair biomarkers and immune profiling for temozolomide and olaparib in metastatic colorectal cancer. Cancer Res. Commun. 3, 1132\u20131139 (2023).","journal-title":"Cancer Res. Commun."},{"key":"72204_CR35","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1634\/theoncologist.2018-0433","volume":"24","author":"YK Chae","year":"2019","unstructured":"Chae, Y. K. et al. Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer. Oncologist 24, 820\u2013828 (2019).","journal-title":"Oncologist"},{"key":"72204_CR36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jtho.2019.12.001","volume":"15","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for patients with NSCLC Treated wWith PD-(L)1 inhibitors. J. Thorac. Oncol. 15, 556\u2013567 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"72204_CR37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41416-022-01822-6","volume":"127","author":"H Elomaa","year":"2022","unstructured":"Elomaa, H. et al. Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer. Br. J. Cancer 127, 514\u2013523 (2022).","journal-title":"Br. J. Cancer"},{"key":"72204_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.lungcan.2018.01.022","volume":"117","author":"S Barua","year":"2018","unstructured":"Barua, S. et al. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. Lung Cancer 117, 73\u201379 (2018).","journal-title":"Lung Cancer"},{"key":"72204_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15095","volume":"8","author":"JL Carstens","year":"2017","unstructured":"Carstens, J. L. et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat. Commun. 8, 15095 (2017).","journal-title":"Nat. Commun."},{"key":"72204_CR40","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1158\/0008-5472.CAN-06-4806","volume":"67","author":"J Galon","year":"2007","unstructured":"Galon, J., Fridman, W. H. & Pag\u00e8s, F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 67, 1883\u20131886 (2007).","journal-title":"Cancer Res."},{"key":"72204_CR41","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman, W. H., Pag\u00e8s, F., Saut\u00e8s-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298\u2013306 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"72204_CR42","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello, D. V. F. et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538\u2013543 (2018).","journal-title":"Nature"},{"key":"72204_CR43","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","volume":"82","author":"L Jenkins","year":"2022","unstructured":"Jenkins, L. et al. Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade. Cancer Res. 82, 2904\u20132917 (2022).","journal-title":"Cancer Res."},{"key":"72204_CR44","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","volume":"12","author":"JA Grout","year":"2022","unstructured":"Grout, J. A. et al. Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumors. Cancer Discov. 12, 2606\u20132625 (2022).","journal-title":"Cancer Discov."},{"key":"72204_CR45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11523-015-0397-2","volume":"11","author":"F Pietrantonio","year":"2016","unstructured":"Pietrantonio, F. et al. Dose-dense temozolomide in patients with MGMT-silenced chemorefractory colorectal cancer. Target Oncol. 11, 337\u2013343 (2016).","journal-title":"Target Oncol."},{"key":"72204_CR46","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41592-021-01274-5","volume":"18","author":"P Jiang","year":"2021","unstructured":"Jiang, P. et al. Systematic investigation of cytokine signaling activity at the tissue and single-cell levels. Nat. Methods 18, 1181\u20131191 (2021).","journal-title":"Nat. Methods"},{"key":"72204_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28020-5","volume":"13","author":"P Danaher","year":"2022","unstructured":"Danaher, P. et al. Advances in mixed cell deconvolution enable quantification of cell types in spatial transcriptomic data. Nat. Commun. 13, 385 (2022).","journal-title":"Nat. Commun."},{"key":"72204_CR48","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/bioinformatics\/bty895","volume":"35","author":"A Zhu","year":"2019","unstructured":"Zhu, A., Ibrahim, J. G. & Love, M. I. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics 35, 2084\u20132092 (2019).","journal-title":"Bioinformatics"},{"key":"72204_CR49","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41378-019-0104-z","volume":"5","author":"D Migliozzi","year":"2019","unstructured":"Migliozzi, D. et al. Microfluidics-assisted multiplexed biomarker detection for in situ mapping of immune cells in tumor sections. Microsyst. Nanoeng. 5, 59 (2019).","journal-title":"Microsyst. Nanoeng."},{"key":"72204_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"72204_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-S16-S4","volume":"14","author":"D Laksameethanasan","year":"2013","unstructured":"Laksameethanasan, D., Tan, R., Toh, G. & Loo, L. H. cellXpress: a fast and user-friendly software platform for profiling cellular phenotypes. BMC Bioinform. 14, S4 (2013).","journal-title":"BMC Bioinform."},{"key":"72204_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v032.i06","volume":"32","author":"T Benaglia","year":"2009","unstructured":"Benaglia, T., Chauveau, D., Hunter, D. R. & Young, D. S. mixtools: an R package for analyzing mixture models. J. Stat. Softw. 32, 1\u201329 (2009).","journal-title":"J. Stat. Softw."},{"key":"72204_CR53","doi-asserted-by":"publisher","first-page":"e9391","DOI":"10.7717\/peerj.9391","volume":"8","author":"MK Konopi\u0144ski","year":"2020","unstructured":"Konopi\u0144ski, M. K. Shannon diversity index: a call to replace the original Shannon\u2019s formula with unbiased estimator in the population genetics studies. PeerJ 8, e9391 (2020).","journal-title":"PeerJ"},{"key":"72204_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-020-06832-3","volume":"21","author":"J Bergenstr\u00e5hle","year":"2020","unstructured":"Bergenstr\u00e5hle, J., Larsson, L. & Lundeberg, J. Seamless integration of image and molecular analysis for spatial transcriptomics workflows. BMC Genom. 21, 482 (2020).","journal-title":"BMC Genom."},{"key":"72204_CR55","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1016\/j.csbj.2021.06.043","volume":"19","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. & Carmona, S. J. UCell: robust and scalable single-cell gene signature scoring. Comput. Struct. Biotechnol. J. 19, 3796\u20133798 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"72204_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72204-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72204-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72204-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T06:57:52Z","timestamp":1785999472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72204-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72204"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72204-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Since the version of the article initially published, the text \u201cas well as by the Italian Ministry of Health with Ricerca Corrente funds\u201d has been added to the Acknowledgements section in the HTML and PDF versions of the article.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S. reported attending advisory board meetings for Bristol Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, MSD, GSK, DKSH, Astellas, Pierre-Fabre, Tavotek; receiving honoraria for talks from MSD, Eli Lilly, BMS, Roche, Taiho, Astra Zeneca, DKSH, Ipsen, Daiichi Sankyo, Beigene, Astellas; receiving travel support from Roche, Astra Zeneca, Taiho, Eisai, DKSH, Ipsen, Paxman Coolers, Cytomed Therapeutics; receiving research funding from Paxman Coolers, MSD, Natera, CytoMed Therapeutics and has patents pending with licensing to Paxman (US20230414444A1) and Auristone (WO2020130948A1) outside the submitted work. F.P. reported receiving institutional research grants from Lilly, BMS, Incyte, AstraZeneca, Amgen, Agenus, Rottapharm, Johnson&Johnson, personal honoraria as an invited speaker from BeiGene, Daiichi-Sankyo, Seagen, Astellas, Ipsen, AstraZeneca, Servier, Bayer, Takeda, Johnson & Johnson, BMS, MSD, Amgen, Merck-Serono, Pierre-Fabre, Incyte, AstraZeneca, advisory\/consultancy from BMS, MSD, Amgen, Pierre-Fabre, Johnson & Johnson, Servier, Bayer, Takeda, Astellas, GSK, Daiichi-Sankyo, Pfizer, BeiGene, Jazz Pharmaceuticals, Incyte, Rottapharm, Merck-Serono, Italfarmaco, Gilead, AstraZeneca, Agenus, AstraZeneca. AR reported receiving personal fees from Servier and MSD. FMorano reported research funding (to Institution) from Incyte; personal honoraria as invited speaker from Eli Lilly, Pierre Fabre and Servier. L.H.L., J.Y.J.L., J.P.S.Y., and J.C.T.L. are co-founders and shareholders of ImmunoQs Pte. Ltd. L.H.L. and J.Y.J.L. performed the multiplex image analyses as staff of ImmunoQs Pte. Ltd., and wrote and reviewed the image analysis methods as staff of BII, A*STAR, who originally developed the methods. All other authors do not have any conflict of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6294"}}